BioArctic AB

STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028. As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,324,449. This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 29, 2026, at 6:30pm CET. For further information, please contact: Oskar Bosson, VP Communications and Investor Relations E-mail: [email protected] Telephone: +46 704 107 180 Jenny Ljunggren, External Communications and Investor Relations Manager E-mail: [email protected] Telephone: +46 76 013 86 08 About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit . This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion (approximately SEK 17.6 billion) for the company's fiscal year (FY) 2028, which ends in March 2029. Eisai's presentation can be found on This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 25, 2026, at 09:15 CET. For further information, please contact: Oskar Bosson, VP Communications and Investor Relations E-mail: [email protected] Telephone: +46 704 107 180 Jenny Ljunggren, External Communications and Investor Relations Manager E-mail: [email protected] Telephone: +46 76 013 86 08 About Leqembi® (lecanemab) Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. In the US, Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the 'Commercial Insurance Innovative Drug List', recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA. The PDUFA date is set to August 24, 2026. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review. Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and Eisai Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales. About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit . [1] Simulation not to be seen as guidance according to Eisai This information was brought to you by Cision The following files are available for download: SOURCE BioArctic 21% more press release views with Request a Demo

STOCKHOLM 斯德哥尔摩, ，May 25, 2026 2026年5月25日/PRNewswire/ -- /PRNewswire/ --BioArctic AB's (publ) BioArctic AB（公众公司）(NASDAQ Stockholm: BIOA B) （纳斯达克斯德哥尔摩：BIOA B）partner Eisai today published a presentation including a simulation 合作伙伴卫材今天发布了一份包含模拟的演示文稿[1] [1]of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion (approximately SEK 17.6 billion) for the company's fiscal year (FY) 2028, which ends in March 2029. Leqembi未来潜在销售额。根据卫材的模拟，Leqembi的销售额将在公司2028财年（截至2029年3月）达到约3000亿日元（约合176亿瑞典克朗）。Eisai's presentation can be found on 卫材的演讲可以找到在 https://www.eisai.com/ir/library/presentations/index.html https://www.eisai.com/ir/library/presentations/index.htmlThis is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. 这是BioArctic AB（publ）根据欧盟市场滥用法规要求必须披露的信息。The information was released for public disclosure, through the agency of the contact person below, on May 25, 2026, at 09:15 CET. 该信息于2026年5月25日9时15分（欧洲中部时间），通过以下联系人公开披露。For further information, please contact: 如需更多信息，请联系：Oskar Bosson, VP Communications and Investor Relations 奥斯卡·博森，副总裁，通信与投资者关系E-mail: 电子邮件：[emailprotected] 电子邮件地址Telephone: +46 704 107 180 电话：+46 704 107 180JennyLjunggren, External Communications and Investor Relations Manager 珍妮·容格伦，外部沟通与投资者关系经理 E-mail: 电子邮件：[emailprotected] 电子邮件地址Telephone: +46 76 013 86 08 电话：+46 76 013 86 08AboutLeqembi® 关于Leqembi®(lecanemab) （lecanemab）Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Leqembi 是 BioArctic 与卫材战略研究联盟的成果。它是一种人源化的免疫球蛋白伽马1（IgG1）单克隆抗体，针对β淀粉样蛋白（Aβ）的聚集可溶性（原纤维）和不可溶形式。Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. Leqembi已在53个国家获得批准，另有6个国家正在审查中。在最初18个月每两周一次的治疗阶段之后，包括英国、中国、美国和日本在内的7个国家已批准每四周一次的静脉（IV）维持剂量治疗，同时已在12个国家和地区提交了申请。In the US, Leqembi Iqlik™is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the 'Commercial Insurance Innovative Drug List', recently introduced by the National Healthcare Security Administration (NHSA) of China.In January 2026, Eisai's supplemental Biologics License Application regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA. 在美国，Leqembi Iqlik™ 已获准通过自动注射器进行皮下给药，用于早期阿尔茨海默病的维持治疗。2025年11月，Leqembi的皮下制剂新药申请在日本提交。2025年12月，Leqembi被列入中国国家医疗保障局（NHSA）最近发布的《商业保险创新药物名单》。2026年1月，卫材关于Leqembi Iqlik皮下起始剂量的补充生物制品许可申请获得了美国FDA的优先审查。The PDUFA date is set to August 24, 2026. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review.. PDUFA日期定为2026年8月24日。2026年1月，Leqembi皮下注射制剂的生物制品许可申请在中国获得受理，次月该申请被指定为优先审查。Since July 2020,Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. 自2020年7月以来，卫材（Eisai）在临床前阿尔茨海默病患者中进行的lecanemab三期临床研究（AHEAD 3-45）一直在进行。这些患者临床表现正常，但大脑中β淀粉样蛋白水平处于中等或升高状态。该研究于2024年10月完成全部招募。AHEAD 3-45是一项为期四年的研究，由卫材、渤健（Biogen）和美国阿尔茨海默病临床试验联盟（Alzheimer's Clinical Trial Consortium）以公私合作的形式开展。该联盟为美国阿尔茨海默病及相关痴呆症的学术临床试验提供基础设施，由美国国立卫生研究院下属的国家老龄化研究所资助。Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.. 自2022年1月以来，由华盛顿大学圣路易斯分校医学院主导的显性遗传阿尔茨海默病网络试验单位（DIAN-TU）开展的针对显性遗传阿尔茨海默病（DIAD）的Tau NexGen临床研究正在进行中，并将lecanemab作为基础抗淀粉样蛋白疗法。About the collaboration between BioArctic and Eisai 关于BioArctic与Eisai的合作Since 2005,BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. 自2005年以来，BioArctic与卫材在开发和商业化用于治疗阿尔茨海默病的药物方面有着长期合作。最重要的协议包括2007年签署的lecanemab抗体开发与商业化协议，以及2015年签署的阿尔茨海默病备用抗体lecanemab的开发与商业化协议。In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. 2014年，卫材和渤健就lecanemab签订了共同开发和商业化协议。卫材负责阿尔茨海默病产品的临床开发、上市申请和商业化。BioArctic拥有在北欧地区商业化lecanemab的权利，目前正与卫材一起准备在北欧的商业化工作。BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.. BioArctic无需承担lecanemab在阿尔茨海默病中的开发成本，并有权获得与销售里程碑相关的付款以及全球销售的特许权使用费。AboutBioArctic AB 关于BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. BioArctic AB（publ）是一家瑞典生物制药公司，专注于研发能够延缓或阻止神经退行性疾病进展的创新疗法。该公司发明了Leqembi®（lecanemab）——全球首款被证明可以减缓疾病进展并减轻早期阿尔茨海默病认知障碍的药物。Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Leqembi 由 BioArctic 的合作伙伴 Eisai 共同开发，Eisai 负责全球的监管互动和商业化。除了 Leqembi，BioArctic 还拥有针对帕金森病和肌萎缩侧索硬化症（ALS）的抗体，以及更多针对阿尔茨海默病的项目在内的广泛研究组合。Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit . 几个项目利用了该公司的专有技术BrainTransporter™，这项技术有可能主动将抗体输送到血脑屏障，从而提高治疗效果。BioArctic的B股（BIOA B）在纳斯达克斯德哥尔摩大盘股上市。欲了解更多信息，请访问。www.bioarctic.com www.bioarctic.com. 。[1] [1]Simulation not to be seen as guidance according to Eisai 根据卫材公司的说法，模拟结果不应被视为指导。This information was brought to you by Cision 此信息由Cision提供给您http://news.cision.com http://news.cision.comhttps://news.cision.com/bioarctic/r/bioarctic-s-partner-eisai-presents-sales-simulation-of-potential-future-sales-of-leqembi--at-its-inv,c4352522 https://news.cision.com/bioarctic/r/bioarctic的合作伙伴卫材在其投资者会议上展示了leqembi未来潜在销售额的销售预测,c4352522The following files are available for download: 以下文件可供下载：https://mb.cision.com/Main/9978/4352522/4110720.pdf https://mb.cision.com/Main/9978/4352522/4110720.pdf​​​​​​​BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day BioArctic的合作伙伴卫材在其投资者关系日上展示了Leqembi®未来潜在销售额的销售模拟。SOURCE BioArctic 来源 BioArctic21 21% %more press release views with 更多新闻发布视图与 Request a Demo 请求演示